Key Takeaways Zimmer Biomet Holdings, Inc. (ZBH) recently inked an exclusive collaboration agreement with OneStep, the FDA-listed digital fall prevention and mobility intelligence platform. The collaboration is aimed at delivering a comprehensive set of mobility data to further empower surgeons to track recovery progress more effectively following joint replacement surgery. ZBH Stock's Likely Trend Following the News Following the announcement, Zimmer Biomet shares slipped 1.6% yesterday. On a promising not ...

华尔街最受热议、且对市场影响显著的分析师评级报告现已汇总呈现。以下是由 The Fly 整理的、投资 者今日需重点关注的评级变动信息。 五大评级上调个股 1. 罗库（ROKU）：摩根士丹利将其评级从 "减持" 上调至 "增持"，目标价由 85 美元上调至 135 美 元。该机构指出，得益于数字广告市场的强劲表现，2026 年美国广告支出有望实现 "稳健" 增 长。 2. 奥克塔（OKTA）：杰富瑞在其 2026 年软件行业展望报告中，将奥克塔评级从 "持有" 上调至 "买 入"，目标价由 90 美元上调至 125 美元。该机构在研报中向投资者表示，奥克塔正着力打造完整 的身份认证平台，有望把握智能代理需求增长的机遇，发展潜力巨大。 3. 赛富时旗下 ServiceNow（NOW）：古根海姆将其评级从 "卖出" 上调至 "中性"。该机构表示，此 次评级上调的依据是当前股价已低于此前设定的目标价，估值具备吸引力。 4. 罗克韦尔自动化（ROK）：高盛将其评级从 "卖出" 上调至 "中性"，目标价由 329 美元上调至 448 美元。高盛在研报中称，在新任管理层的带领下，公司正处于结构性提价的初期阶段，此举 有望在 ...

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly.Top 5 Upgrades: Morgan Stanley upgraded L3Harris Technologies (LHX) to Overweight from Equal Weight with a price target of $367, up from $350, as part of its 2026 outlook for aerospace and defense. The firm sees aerospace and defense as attractive going into 2026, saying demand continues to outpace supply growth. Morgan Stanley a ...

®OneStep's Clinically Validated Mobility Intelligence Technology to Integrate into Zimmer Biomet's mymobility Care Management Platform to Further Enhance Recovery Monitoring WARSAW, Ind., Dec. 16, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, and OneStep, the FDA-listed digital fall prevention and mobility intelligence platform, today announced an exclusive collaboration agreement aimed at delivering the orthopedic industry's most comprehensive se ...

With a market cap of $18.4 billion, Zimmer Biomet Holdings, Inc. (ZBH) is a leading global medical technology company specializing in orthopedic implants and surgical solutions. The Indiana-based  company’s portfolio includes joint replacement products, trauma and sports medicine devices, spine and craniomaxillofacial technologies, and robotic surgery platforms. Companies worth more than $10 billion are generally labeled as “large-cap” stocks and Zimmer Biomet fits this criterion perfectly. Serving hospit ...

December 2, 2025 11:00 AM GMT US Healthcare Research | North America 2026 Hospital Outlook Survey Our AlphaWise survey of 100 US-based hospital executives supports a steady environment for medical devices into '26. The survey provides increased confidence in the continuation of capex spending momentum with some prioritization shifts, improving utilization and stable medical acuity. M We conducted an AlphaWise survey of 100 hospital executives in November 2025, representing a total of ~39,500 hospital beds ( ...

Core Insights - Bragar Eagel & Squire, P.C. is investigating potential claims against Gauzy Ltd. and Zimmer Biomet Holdings, concerning possible violations of federal securities laws and unlawful business practices [1] Gauzy Ltd. (NASDAQ:GAUZ) - On November 14, 2025, Gauzy announced a delay in releasing its third-quarter financial results due to the initiation of insolvency proceedings for three subsidiaries in France [6] - Following this announcement, Gauzy's stock price dropped by $1.35 per share, a decline of 33.58%, closing at $2.67 per share [6] Zimmer Biomet Holdings, Inc. (NYSE:ZBH) - On November 5, 2025, Zimmer Biomet reported third-quarter net sales of $2 billion, which fell short of consensus estimates of $2.01 billion [6] - The company revised its full-year organic revenue growth outlook to a range of 3.5% to 4%, down from a previous range of 3.5% to 4.5% [6] - Zimmer Biomet experienced weakness in international markets and non-core businesses, with challenges from distributors and order cancellations in the Middle East and Eastern Europe impacting results [6] - Following the earnings report, Zimmer Biomet's stock price fell by $15.63 per share, a decrease of 15.5%, closing at $87.55 per share [6]

Core Insights - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Zimmer Biomet and its executives [1] - Zimmer Biomet reported third-quarter 2025 net sales of $2 billion, which fell short of the consensus estimate of $2.01 billion [2] - The company revised its full-year organic revenue growth outlook down to a range of 3.5% to 4%, from a previous range of 3.5% to 4.5% [2] - Weakness in international markets and non-core businesses, along with order cancellations in the Middle East and Eastern Europe, negatively impacted results [2] - The stock price of Zimmer Biomet dropped by $15.63 per share, or 15.5%, closing at $87.55 on November 5, 2025, following the earnings announcement [2]

Core Insights - The 24th Chinese Orthopaedic Association (COA) conference showcased significant advancements in orthopedic technology, emphasizing the integration of robotics, navigation, imaging, and biomaterials under the theme "Digital Intelligence in Orthopedics" [2] - The conference attracted 20,188 registered participants and received 37,222 submissions, indicating a strong interest in orthopedic innovations [2] Group 1: Robotics and Navigation Systems - Surgical robots and navigation systems are expanding across various orthopedic fields, moving beyond joint surgeries to include spine, trauma, and sports medicine, focusing on precision and standardization [4] - Companies like Stryker, Tianzhihang, and others are presenting comprehensive orthopedic platforms that integrate imaging, navigation, and robotic arms, forming a closed-loop system for enhanced surgical outcomes [4] - The Trinity system by Tuo Dao Medical demonstrates a unified platform for rapid switching between surgical procedures, showcasing advancements in AI planning and real-time navigation [19] Group 2: Biomaterials and Bone Repair - The competition in bone repair and biomaterials is intensifying, with companies offering innovative solutions such as absorbable screws and 3D-printed bioceramics, focusing on osteogenic activity and infection resistance [4] - Smartbone and other manufacturers are introducing advanced materials that not only fill defects but also promote bone regeneration and integration [4] Group 3: Domestic Innovations - Domestic companies are accelerating the development of high-end joint prosthetics and key materials, with a focus on integrating materials, prosthetic design, and manufacturing processes [4] - The collaboration between local firms and international companies is shifting from product showcases to establishing standards and ecosystems, enhancing the overall orthopedic landscape [4] Group 4: Key Product Launches - Stryker highlighted its latest products, including the Mako robotic system, which integrates multiple surgical techniques for hip and knee replacements, enhancing precision and efficiency [5][7] - Rosenboht signed a strategic partnership with the Chinese University of Hong Kong to advance intelligent surgical technologies, aiming for more precise and minimally invasive orthopedic procedures [12][14] - The launch of the "Panshi Self-Pressing 3D Partition Bone Trabecular Biological Knee Prosthesis" by Jiashite Medical showcases advancements in mechanical stability and biological fixation [40][42] Group 5: Technological Integration - Companies are increasingly focusing on integrating AI and imaging technologies to enhance surgical precision and safety, as seen in the solutions presented by Meiya Optical and other firms [46][50] - The introduction of AR navigation systems by Linyan Medical represents a significant technological advancement, improving the visibility and accuracy of spinal surgeries [53][55] Group 6: Comprehensive Solutions - The conference highlighted the importance of comprehensive solutions that encompass preoperative planning, intraoperative guidance, and postoperative evaluation, as demonstrated by various exhibitors [4][60] - Companies like Weigao and others are showcasing integrated solutions that leverage digital technologies to enhance the entire orthopedic treatment process [100][102]

Core Insights - The Law Offices of Frank R. Cruz is investigating Zimmer Biomet Holdings, Inc. for potential violations of federal securities laws on behalf of investors [1] - Zimmer reported third quarter 2025 financial results with net sales of approximately $2 billion, citing weaknesses in Latin America, Emerging Markets in Europe, and non-core businesses [2] - The company lowered its full-year organic revenue growth forecast from 4.5% to 4.0% due to ongoing weakness in restorative therapies and a slowdown in the U.S. revision market for hips and knees [2] - Following the financial results announcement, Zimmer's stock price dropped by $15.63, or 15.2%, closing at $87.55 per share, impacting investors negatively [2]